Under the agreement, Systagenix will co-market EpiFix, MiMedx's proprietary biologic implant processed from amniotic tissue. Systagenix will conduct the first phase of the EpiFix global launch throughout the United States, followed by other countries.
MiMedx will continue selling EpiFix through existing distributor channels.
More Articles on Orthopedic Devices:
US Implantable Medical Devices Demand to Increase 7.7% Annually Through 2015
Exactech's Deferred Prosecution Agreement Expires
BioMimetic Reports 2011 Revenue
MiMedx Signs Distribution Agreement With SystagenixWritten by Laura Miller | March 20, 2012
MiMedx Group announced it signed a global distribution agreement with Systagenix.
© Copyright ASC COMMUNICATIONS 2011. Interested in LINKING to or REPRINTING this content? View our policies here.